Pharmaceuticals company Procter & Gamble Health announced Q3FY25 results Q3FY25 Financial Highlights: The third quarter reported sales of Rs 304 crore, up 23% versus the comparable period previous year PAT of Rs 61 crore, up 31% versus comparable period a year ago, owing to superior brand building activities and supported by strengthened supply chain and go-to-market capabilities. The Board of Directors has recommended a final dividend of Rs 45 per Equity Share, for the Financial Year ending March 31, 2025 Commenting on the results, Milind Thatte, Managing Director, P&G; Health India, said, “This was a period of purposeful transformation and acceleration. We invested in initiatives to address the changing needs of our consumers and healthcare professionals, while strengthening our go-to-market and supply chain capabilities. Our strategy - centered on a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure, helped us build a strong foundation for long-term growth. This integrated strategy continues to guide our efforts to generate sustainable, balanced top- and bottom-line growth, along with value creation for our consumers, customers, and shareholders alike” Result PDF